Physician profile
Scott D Levenson
NPI 1578548186
$132,536.89
in general payments reported to CMS, 2019-2025
43 companies · $19K in 2025
The $19K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $14K · 2021: $10K · 2022: $5,167 · 2023: $17K · 2024: $57K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $69K · Food and Beverage: $14K · Travel and Lodging: $4,779 · Honoraria: $3,000 · Consulting Fee: $1,575 · Education: $80.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,047.50 |
| Food and Beverage | $13,781.03 |
| Travel and Lodging | $4,778.84 |
| Honoraria | $3,000.00 |
| Consulting Fee | $1,575.00 |
| Education | $80.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $42,974.23 | 2024-2025 | Voquezna |
| Abbvie INC. | $41,072.20 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $10,844.48 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $6,125.23 | 2020-2023 | |
| Qol Medical, LLC | $6,100.96 | 2019-2025 | Sucraid, Sucraid |
| Allergan, INC. | $5,174.66 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,278.37 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,204.17 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Redhill Biopharma INC. | $2,068.80 | 2020-2023 | Aemcolo, Talicia, Movantik |
| E.R. Squibb & Sons, L.L.C. | $1,975.00 | 2021-2023 | |
| Janssen Biotech, INC. | $1,740.80 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $1,635.91 | 2019-2025 | Linzess |
| Gilead Sciences, INC. | $1,612.43 | 2019-2025 | Vemlidy |
| Madrigal Pharmaceuticals | $848.40 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $686.35 | 2022-2025 | Ibsrela |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $600.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $478.94 | 2019-2024 | |
| Daiichi Sankyo INC. | $432.82 | 2019-2022 | |
| Celltrion USA INC. | $385.46 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Lilly USA, LLC | $369.49 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $347.94 | 2020-2024 | Dificid |
| Braintree Laboratories, INC. | $303.84 | 2019-2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $298.89 | 2019-2025 | Ocaliva |
| Celgene Corporation | $263.67 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $259.03 | 2019-2024 | Rebyota |
| Vivus LLC | $211.39 | 2020-2025 | Pancreaze |
| Neptune Medical INC. | $200.00 | 2023 | |
| Romark Laboratories, Lc | $189.74 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $117.70 | 2024-2025 | Iqirvo, Bylvay |
| Pfizer INC. | $109.97 | 2019-2025 | |
| Amgen INC. | $106.97 | 2022-2025 | Avsola, Amjevita |
| Genzyme Corporation | $102.57 | 2021-2024 | |
| Endo Pharmaceuticals INC. | $78.49 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $75.27 | 2022-2023 | Dupixent |
| Exact Sciences Corporation | $60.79 | 2024-2025 | Cologuard Collection Kit |
| Echosens North America, INC. | $57.60 | 2024-2025 | Fibroscan, Fibroscan |
| Novo Nordisk INC | $51.50 | 2025 | Wegovy |
| Biocon Biologics INC | $31.34 | 2025 | Yesintek |
| Sandoz INC. | $22.91 | 2023 | Hyrimoz |
| Shire North American Group INC | $22.62 | 2019 | |
| Capsovision, INC. | $15.96 | 2025 | Capsocam Plus |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Levenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.